表纸
市场调查报告书

重症肌无力:市场机会的评估,流行病学的预测,市场趋势,开发中产品分析

Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019

出版商 GervanoRA Data Services LLP 商品编码 920043
出版日期 内容资讯 英文 151 Pages
订单完成后即时交付
价格
Back to Top
重症肌无力:市场机会的评估,流行病学的预测,市场趋势,开发中产品分析 Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019
出版日期: 2020年01月03日内容资讯: 英文 151 Pages
简介

本报告提供全球重症肌无力医药品的市场相关分析,疾病概要和疫情趋势预测,未满足需求与市场机会,主要的资本交易的趋势 (M&A,事业合作等),开发中产品的分析与临床实验的进展,现在、未来的竞争环境,主要企业的SWOT分析,新企业的简介与市场机会等资讯汇整,为您概述为以下内容。

第1章 简介

第2章 摘要整理

  • 分析概要
  • 重症肌无力市场:近来的主要动向
  • 主要的分析结果:推动及阻碍市场要素,市场机会

第3章 重症肌无力:疾病概要

  • 疾病定义与症状
  • 疾病的原因与分类
  • 诊断方法
  • 治疗的演算法和指南
  • 流行病学的调查
    • 全球到目前为止的发病趋势
  • 流行病学的预测
    • 预测手法与前提条件
    • 概率的、流行病学的预测

第4章 重症肌无力市场动态:竞争环境

  • 交易趋势
    • 企业合并、收购 (M&A)
    • 事业合作、协定
    • 授权合约
    • 资本交易
  • 专利分析 (消灭、一般化)
    • 开发平台医药品的专利分析

第5章 重症肌无力:开发平台医药品分析

  • 开发平台医药品分析:各临床实验阶段
    • 第三阶段的开发平台医药品
    • 第二阶段的开发平台医药品
    • 第一阶段的开发平台医药品
    • 前临床阶段的开发平台医药品
    • 初期的研究开发 (R&D) 阶段的开发平台医药品
    • 撤退、中止的开发平台医药品
  • 开发平台医药品分析:各地区
    • 未满足需求与市场机会
  • 开发平台医药品分析:各给药途径
    • 未满足需求与市场机会
  • 开发平台医药品分析:各类药物
    • 未满足需求与市场机会
  • 开发平台医药品分析:各作用机制
    • 未满足需求与市场机会
  • 开发平台医药品分析:各标的
  • 开发平台医药品分析:企业的各类型
  • 开发平台医药品分析:大学、研究机关 - 授权合约的市场机会

第6章 开发平台医药品临床实验阶段:概要和临床实验的里程碑

  • 第三阶段的开发平台医药品:概要和临床实验的里程碑
    • ALEXION PHARMACEUTICALS INC - SOLIRIS (Eculizumab)
    • ALEXION PHARMACEUTICALS INC - ULTOMIRIS
    • ARGENX SE - EFGARTIGIMOD (ARGX-113)
    • CATALYST PHARMA - FIRDAPSE (AMIFAMPRIDINE PHOSPHATE)
    • UCB SA - ROZANOLIXIZUMAB/UCB7665
    • RA PHARMACEUTICALS INC - ZILUCOPLAN
  • 第二阶段的开发平台医药品:概要和临床实验的里程碑
    • IMMUNOVANT - IMVT-1401
    • DAS THERAPEUTICS - GTB-004/DAS-MG
    • MOMENTA PHARMACEUTICALS INC - NIPOCALIMAB (M281)
    • CARTESIAN THERAPEUTICS - DESCARTES-08
    • ALEXION PHARMACEUTICALS INC - ALXN 1830
  • 第一阶段的开发平台医药品:概要和临床实验的里程碑
    • ALPHA CANCER TECHNOLOGIES INC - ACT-101 (AFP)
    • KASHIV BIOSCIENCES LLC/AMNEAL PHARMACEUTICALS - K127 (PYRIDOSTIGMINE)

第7章 重症肌无力的开发平台医药品:核准计划的预测

  • 分析方法
  • 在美国国内/国外的认证计划 (估计)

第8章 市场机会的评估:企业间的互相比较

  • 外部的依赖
  • 开发中产品的组合
  • 市场进入预测
  • 专利与排他性
  • 销售趋势与联盟活动
  • 法规上的特别使用的获得情形
  • 企业的发展

第9章 现在/未来的竞争环境的评估:企业简介

  • 现有企业
    • 主要企业的简介和SWOT分析
      • ALEXION PHARMACEUTICALS INC
      • UCB SA
      • 武田药品工业
      • NOVARTIS AG
      • CATALYST PHARMACEUTICALS INC
  • 新企业
    • 主要的新企业的简介和竞争机会的评估
      • ARGENX SE
      • ALPHA CANCER TECHNOLOGIES INC
      • MOMENTA PHARMACEUTICALS INC
      • RA PHARMACEUTICALS INC
      • VIELA BIO, INC.
      • GT BIOPHARMA
      • IMMUNOVANT, INC
      • KASHIV BIOSCIENCES LLC
      • CARTESIAN THERAPEUTICS, INC
      • AKARI THERAPEUTICS PLC
      • CABALETTA BIO INC
      • NEUROTUNE AG
      • TOLERANZIA AB
      • AHEAD THERAPEUTICS S.L

第10章 简称一览

目录
Product Code: GERPH606

GervanoRA's pipeline analysis and opportunity assessment report "Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019" analyzed and assessed Myasthenia Gravis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Myasthenia Gravis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Drug Class, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Stage of development, Pipeline Analytics by Target and Pipeline Analytics by Companies.

Our comprehensive analysis on the Myasthenia Gravis drug pipeline identified a total of 29 drug candidates undergoing different stages of development- from Early R&D to Phase 3 stage. Among these, seven molecules are in the Phase 3 stage of development, seven molecules are in Phase 2, two molecules are in Phase 1 and a total of 13 molecules are in non clinical stage of development. We have also identified six drug molecules which have been discontinued or terminated due to various reasons from further development for Myasthenia Gravis.

The report has covered more than 25 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 14 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of all Clinical Stage Pipeline Drug Candidates
  • Current and Future Competitive Landscape
  • Key Established Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2 KEY EVENTS IN THE MYASTHENIA GRAVIS COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3. MYASTHENIA GRAVIS DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY STUDIES
    • 3.5.1. GLOBAL AND HISTORICAL TRENDS
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS OF MYASTHENIA GRAVIS DISEASE COMPETITIVE SPACE

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 MERGERS AND ACQUISITIONS
    • 4.1.2 COLLABORATION AGREEMENTS
    • 4.1.3 LICENSING AGREEMENTS
    • 4.1.4 FINANCING DEALS
  • 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE DRUGS ANALYTICS OF MYASTHENIA GRAVIS DISEASE

  • 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE 3 PIPELINE DRUGS
    • 5.1.2. PHASE 2 PIPELINE DRUGS
    • 5.1.3. PHASE 1 PIPELINE DRUGS
    • 5.1.4. PRECLINICAL PIPELINE DRUGS
    • 5.1.5. EARLY R&D PIPELINE DRUGS
    • 5.1.6. WITHDRAWN AND TERMINATED PIPELINE DRUGS
  • 5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE DRUGS ANALYTICS BY TARGET
  • 5.7. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • 5.8. PIPELINE DRUGS ANALYTICS BY UNIVERSITIES AND INSTITUTES - LICENSING OPPORTUNITIES

6. CLINICAL STAGE PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE 3 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • ALEXION PHARMACEUTICALS INC - SOLIRIS (ECULIZUMAB)
  • ALEXION PHARMACEUTICALS INC - ULTOMIRIS
  • ARGENX SE - EFGARTIGIMOD (ARGX-113)
  • CATALYST PHARMA - FIRDAPSE (AMIFAMPRIDINE PHOSPHATE)
  • UCB SA - ROZANOLIXIZUMAB/UCB7665
  • RA PHARMACEUTICALS INC - ZILUCOPLAN
  • 6.2. PHASE 2 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • IMMUNOVANT - IMVT-1401
  • DAS THERAPEUTICS - GTB-004/DAS-MG
  • MOMENTA PHARMACEUTICALS INC - NIPOCALIMAB (M281)
  • CARTESIAN THERAPEUTICS - DESCARTES-08
  • ALEXION PHARMACEUTICALS INC - ALXN 1830
  • 6.3. PHASE 1 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • ALPHA CANCER TECHNOLOGIES INC - ACT-101 (AFP)
  • KASHIV BIOSCIENCES LLC/AMNEAL PHARMACEUTICALS - K127 (PYRIDOSTIGMINE)

7. ESTIMATED APPROVAL TIMELINES OF MYASTHENIA GRAVIS PIPELINE DRUGS

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

8. OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 8.1. EXTERNAL DEPENDENCIES
  • 8.2. PIPELINE PORTFOLIO
  • 8.3. EXPECTED MARKET ENTRIES
  • 8.4. PATENTS AND EXCLUSIVITY
  • 8.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 8.7. COMPANY DEVELOPMENTS

9. ASSESSMENT OF CURRENT AND FUTURE COMPETITIVE LANDSCAPE THROUGH COMPANY PROFILES

  • 9.1. ESTABLISHED COMPANIES
    • 9.1.1. KEY COMPANY PROFILES AND SWOT ANALYSIS
      • 9.1.1.1. ALEXION PHARMACEUTICALS INC
      • 9.1.1.2. UCB SA
      • 9.1.1.3. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 9.1.1.4. NOVARTIS AG
      • 9.1.1.5. CATALYST PHARMACEUTICALS INC
  • 9.2. EMERGING COMPANIES
    • 9.2.1. KEY EMERGING COMPANY PROFILES WITH COMPETITIVE OPPORTUNITY ASSESSMENTS
      • 9.2.1.1 ARGENX SE
      • 9.2.1.2. ALPHA CANCER TECHNOLOGIES INC
      • 9.2.1.3. MOMENTA PHARMACEUTICALS INC
      • 9.2.1.4. RA PHARMACEUTICALS INC
      • 9.2.1.5. VIELA BIO, INC.
      • 9.2.1.6. GT BIOPHARMA
      • 9.2.1.7. IMMUNOVANT, INC
      • 9.2.1.8. KASHIV BIOSCIENCES LLC
      • 9.2.1.9. CARTESIAN THERAPEUTICS, INC
      • 9.2.1.10. AKARI THERAPEUTICS PLC
      • 9.2.1.11. CABALETTA BIO INC
      • 9.2.1.12. NEUROTUNE AG
      • 9.2.1.13. TOLERANZIA AB
      • 9.2.1.14. AHEAD THERAPEUTICS S.L

10. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: SIGNS AND SYMPTOMS OF MG
  • TABLE 03: MYASTHENIA GRAVIS WORLDWIDE EPIDEMIOLOGY (2019) AND FORECAST (2020-2025), IN MILLION
  • TABLE 04: MYASTHENIA GRAVIS US EPIDEMIOLOGY (2019) AND FORECAST (2020-2025), IN MILLION
  • TABLE 05: PHASE 3 MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 06: PHASE 2 MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 07: PRECLINICAL MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 08: TERMINATED DRUGS FOR MG
  • TABLE 09: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY INJECTABLE AS ROA
  • TABLE 10: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY ORAL AS ROA
  • TABLE 11: DRUG CLASSES SCENARIO IN THE MG DRUG PIPELINE
  • TABLE 12: COMMON TARGETS IN THE MG DRUG PIPELINE
  • TABLE 13: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 14: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY UNIVERSITIES
  • TABLE 15: ESTIMATED APPROVAL TIMELINE OF KEY PIPELINE DRUGS FOR MYASTHENIA GRAVIS
  • TABLE 16: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 17: MAJOR PRODUCTS OF AMGEN WITH SALES IN FIRST NINE MONTHS FOR 2018 AND 2019 RESPECTIVELY
  • TABLE 18: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO HEMATOLOGY THERAPEUTIC AREA
  • TABLE 19: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO NEUROLOGY THERAPEUTIC AREA
  • TABLE 20: RESEARCH AND DEVELOPMENT ACTIVITIES OF ALEXION
  • TABLE 21: RECENT DEVELOPMENTS OF ALEXION
  • TABLE 22: MAJOR PRODUCTS OF UCB SA
  • TABLE 23: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO IMMUNOLOGY THERAPEUTIC AREA
  • TABLE 24: RESEARCH AND DEVELOPMENT ACTIVITIES OF UCB
  • TABLE 25: RECENT DEVELOPMENTS OF UCB
  • TABLE 26: MAJOR PRODUCTS OF TAKEDA
  • TABLE 27: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO ONCOLOGY THERAPEUTIC AREA
  • TABLE 28: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO GASTROENTEROLOGY THERAPEUTIC AREA
  • TABLE 29: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO RARE DISEASE THERAPEUTIC AREA
  • TABLE 30: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO NEUROSCIENCE THERAPEUTIC AREA
  • TABLE 31: RESEARCH AND DEVELOPMENT ACTIVITIES OF TAKEDA
  • TABLE 32: RECENT DEVELOPMENTS OF TAKEDA
  • TABLE 33: NOVARTIS'S SALES IN MILLION $ OF TOP 10 PRODUCTS IN 9 MONTHS IN 2019
  • TABLE 34: NOVARTIS'S IN REGISTRATION MOLECULES
  • TABLE 35: NOVARTIS'S PHASE 3 MOLECULES
  • TABLE 36: NOVARTIS'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 37: NOVARTIS'S RECENT DEVELOPMENTS
  • TABLE 38: NOVARTIS'S ANTICIPATED MILESTONES
  • TABLE 39: CATALYST PRODUCT PIPELINE
  • TABLE 40: CATALYST RESEARCH AND DEVELOPMENTS
  • TABLE 41: CATALYST RECENT DEVELOPMENTS
  • TABLE 42: ARGENX PIPELINE ASSETS
  • TABLE 43: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF ARGENX SE
  • TABLE 44: ANTICIPATED NEAR FUTURE MILESTONES OF ARGENX SE
  • TABLE 45: CONFERENCES OF ARGENX SE
  • TABLE 46: ACT PIPELINE ASSETS
  • TABLE 47: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF ACT
  • TABLE 48: MOMENTA PIPELINE ASSETS
  • TABLE 49: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF MOMENTA
  • TABLE 50: ANTICIPATED NEAR FUTURE MILESTONES OF MOMENTA
  • TABLE 51: RA PHARMACEUTICALS PIPELINE ASSETS
  • TABLE 52: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF RA PHARMACEUTICALS
  • TABLE 53: PRESENTATIONS AND PUBLICATIONS OF RA PHARMACEUTICALS
  • TABLE 54: VIELA BIO PIPELINE ASSETS
  • TABLE 55: RECENT DEVELOMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF VIELA BIO
  • TABLE 56: ANTICIPATED NEAR FUTURE MILESTONES OF VIELA BIO
  • TABLE 57: GT BIOPHARMA PIPELINE ASSETS
  • TABLE 58: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF GT BIOPHARMA
  • TABLE 59: IMMUNOVANT PIPELINE ASSETS
  • TABLE 60: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF IMMUNOVANT
  • TABLE 61: ANTICIPATED NEAR FUTURE MILESTONES OF IMMUNOVANT
  • TABLE 62: PRESENTATION OF IMMUNOVANT
  • TABLE 63: KASHIV BIOSCIENCES 505(B) (2) PIPELINE ASSETS
  • TABLE 64: KASHIV BIOSCIENCES BIOSMILARS PIPELINE ASSETS
  • TABLE 65: KASHIV BIOSCIENCES PRODRUGS PIPELINE ASSETS
  • TABLE 66: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF KASHIV BIOSCIENCES
  • TABLE 67: CARTESIAN THERAPEUTICS PIPELINE ASSETS
  • TABLE 68: RECENT DEVELOMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF CARTESIAN
  • TABLE 69: AKARI PIPELINE ASSETS
  • TABLE 70: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF AKARI THERAPEUTICS
  • TABLE 71: CABALETTA PIPELINE ASSETS
  • TABLE 72: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF CABALETTA
  • TABLE 73: NEUROTUNE AG PIPELINE ASSETS
  • TABLE 74: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF NEUROTUNE AG
  • TABLE 75: TOLERANZIA AB PIPELINE ASSETS
  • TABLE 76: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF TOLERANZIA AB
  • TABLE 77: AHEAD THERAPEUTICS PIPELINE ASSETS
  • TABLE 78: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF AHEAD THERAPEUTICS

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN MYASTHENIA GRAVIS DISEASE AREA
  • FIGURE 02: MYASTHENIA GRAVIS DISEASE CLASSIFICATION
  • FIGURE 03: MYASTHENIA GRAVIS WORLDWIDE EPIDEMIOLOGY FORECAST (2019-2025)
  • FIGURE 04: MYASTHENIA GRAVIS US EPIDEMIOLOGY FORECAST (2019-2025)
  • FIGURE 05: MYASTHENIA GRAVIS DEALS SCENARIO
  • FIGURE 06: MYASTHENIA GRAVIS PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 07: MYASTHENIA GRAVIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 08: MYASTHENIA GRAVIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 09: SPLIT UP BY HSD WITH RESPECT TO INJECTABLE ROUTE
  • FIGURE 10: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 11: TOP 5 COMPANIES WITH RESEARCH AND DEVELOPMENT EXPENSES MADE BETWEEN 2014 AND 2018
  • FIGURE 12: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 13: EXPECTED U.S MARKET ENTRIES IRRESPECTIVE OF MYASTHENIA GRAVIS TREATMENTS
  • FIGURE 14: EXPECTED U.S MARKET ENTRY WITH RESPECT TO MYASTHENIA GRAVIS TREATMENT
  • FIGURE 15: PATENT PORTFOLIO COMPARISON OF TOP 10 EMERGING COMPANIES
  • FIGURE 16: TIME LINE OF PATENT EXPIRIES IRRESPECTIVE OF MYASTHENIA GRAVIS TREATMENTS
  • FIGURE 17: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO MYASTHENIA GRAVIS
  • FIGURE 18: RANKING TOP 6 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 19: R&D EXPENSES AS WELL AS NET SALES FOR YEARS 2016, 2017 AND 2018 MADE BY ALEXION
  • FIGURE 20: PRODUCT SALES AND R&D EXPENSES FOR THE FIRST NINE MONTHS OF 2018 AND 2019
  • FIGURE 21: UCB'S RESEARCH AND DEVELOPMENT EXPENSES AND NET SALES FOR 2017 AND 2018
  • FIGURE 22: UCB'S SALES BREAKDOWN FOR FIRST SIX MONTHS OF 2019
  • FIGURE 23: REVENUES ATTAINED, R &D EXPENSES BY TAKEDA ENDED ON 31 MARCH 2018 & 2019
  • FIGURE 24: GEOGRAPHICAL DISTRIBUTION OF REVENUES EARNED BY TAKEDA IN 2019
  • FIGURE 25: NOVARTIS'S REVENUES EARNED IN MILLION $ FOR 2016, 2017 AND 2018
  • FIGURE 26: NOVARTIS'S BREAKDOWN OF REVENUES EARNED IN THE YEAR END OF 2018
  • FIGURE 27: RESEARCH AND DEVELOPMENT EXPENSES FOR THE YEAR ENDED DECEMBER 31, 2018, 2017 (MILLION $)
  • FIGURE 28: RESEARCH AND DEVELOPMENT EXPENSE OF ARGENX SE IN THOUSANDS (2017 AND 2018)
  • FIGURE 29: R&D EXPENSE OF MOMENTA PHARMACEUTICALS IN THOUSANDS (2016, 2017 AND 2018)
  • FIGURE 30: RESEARCH AND DEVELOPMENT EXPENSE OF RA PHARMACEUTICALS IN THOUSANDS (2017 AND 2018)
  • FIGURE 31: RESEARCH AND DEVELOPMENT EXPENSE OF AKARI THERAPEUTICS IN US DOLLARS (2017 AND 2018)
  • FIGURE 32: R&D EXPENSES OF CABALETTA FOR THREE & NINE MONTHS IN THOUSANDS (ENDED SEPTEMBER 30, 2019)
Back to Top